AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study
Fabrizio Stocchi(San Raffaele University of Rome), Claudia Trenkwalder(Paracelsus Elena Klinik Kassel), Olivier Rascol(Université Toulouse III - Paul Sabatier), Werner Poewe(University of Verona), Haitao Gao(Novartis (United States)), Eduardo Tolosa(Biomedical Research Networking Center on Neurodegenerative Diseases), Robert A. Hauser(University of South Florida), Christopher Kenney(Novartis (United States)), Martin Merschhemke(Novartis (Switzerland)), Ana Graf(Novartis (Switzerland)), Jennifer Nagel(Novartis (Switzerland)), Mark Stacy(Duke University), Anthony E. Lang(Unknown), A. Destée(Inserm), Nobutaka Hattori(RIKEN Center for Brain Science)
Cited by 137
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
|Nature Genetics|2000|2k